• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CareDx Inc. (Amendment)

    2/13/24 5:00:59 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    SC 13G/A 1 tv0531-caredxinc.htm SCHEDULE 13G/A caredxinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  CareDx Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  14167L103

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  14167L103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    23,749

    7.  SOLE DISPOSITIVE POWER

    4,075,831

    8.  SHARED DISPOSITIVE POWER

    43,851

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,119,682

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.62%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    CareDx Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    8000 Marina Boulevard
    Brisbane, CA 94005

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    14167L103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $CDNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    8/26/2025Mkt Perform
    William Blair
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $CDNA
    SEC Filings

    View All

    SEC Form S-8 filed by CareDx Inc.

    S-8 - CareDx, Inc. (0001217234) (Filer)

    11/4/25 4:26:57 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by CareDx Inc.

    10-Q - CareDx, Inc. (0001217234) (Filer)

    11/4/25 4:13:11 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Regulation FD Disclosure

    8-K - CareDx, Inc. (0001217234) (Filer)

    11/4/25 4:09:22 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CareDx to Participate in Upcoming Investor Conferences

    CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences: Stephens Investment Conference in Nashville, TN. Fireside chat on Wednesday, November 19, 2025, at 8am CT. Piper Sandler Healthcare Conference in New York, NY. Presentation on Wednesday, December 3, 2025, at 4:30pm ET. Live and archived webcasts of the presentations will be available on the "Events and Presentations" section of the CareDx investor rela

    11/10/25 8:00:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On November 4, 2025, as an inducement material to acceptance of employment with CareDx, 49 new employees were awarded restricted stock units (RSUs) for an aggregate of 113,250 shares of common stock. Additionally, on November 4, 2025, CareDx granted to Dr. Jeffrey Teuteberg, the Company's newly appointed Chief Medical Officer, 88,180 RSUs as an inducement material to Dr. Teuteberg's acceptan

    11/7/25 4:05:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

    CareDx Extends Leadership in Kidney Transplant Molecular Testing with Launch of Unique Tissue-Based Gene Expression Assay – HistoMap Kidney CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data presentations featuring CareDx technologies at American Society of Nephrology (ASN) Kidney Week 2025, underscoring the power of molecular biomarkers to advance transplant care. The company also announced the launch of HistoMap™ Kidney, a tissue-based molecular test that objec

    11/6/25 8:00:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Secretary and General Counsel Novack Jeffrey Adam sold $41,723 worth of shares (2,688 units at $15.52), decreasing direct ownership by 2% to 105,218 units (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    11/10/25 4:14:40 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,152 shares, decreasing direct ownership by 2% to 107,906 units (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    11/7/25 5:22:41 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,872 shares, decreasing direct ownership by 3% to 110,058 units (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    11/4/25 4:03:02 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on CareDx

    William Blair initiated coverage of CareDx with a rating of Mkt Perform

    8/26/25 8:17:26 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

    1/15/25 7:29:19 AM ET
    $CDNA
    Medical Specialities
    Health Care

    Wells Fargo initiated coverage on CareDx with a new price target

    Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00

    8/28/24 7:38:28 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Leadership Updates

    Live Leadership Updates

    View All

    CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

    Renowned Transplant Clinician to Lead CareDx Global Medical Affairs CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of experience in clinical transplantation, including senior leadership roles at Stanford University and the University of Pittsburgh Medical Center. He is board certified in Heart Failure/Cardiac Transplantation

    10/27/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

    CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the appointment of Suresh Gunasekaran to its Board of Directors. Suresh currently serves as President and Chief Executive Officer at UCSF Health, an internationally renowned health system for providing highly specialized and innovative care, including solid organ and bone marrow transplantation. Suresh has more than 20 years of executive leadership experience in healthcare administration and information technology, with a proven track record of driving operational

    10/22/25 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

    CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. "Nathan's deep f

    8/6/25 4:57:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Financials

    Live finance-specific insights

    View All

    CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a

    10/21/25 8:00:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Report Second Quarter 2025 Financial Results

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-274-8461 for domestic callers or 1-203-518-9814 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, plea

    7/23/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Report First Quarter 2025 Financial Results

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

    4/8/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/14/24 5:13:57 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/8/24 2:34:10 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/5/24 6:07:26 AM ET
    $CDNA
    Medical Specialities
    Health Care